1,800
Participants
Start Date
March 31, 2009
Primary Completion Date
May 31, 2009
Study Completion Date
October 31, 2009
Q/LAIV (MEDI3250)
0.2 mL dose at Day 0
FluMist/B/Yamagata
0.2 mL dose at Day 0
FluMist/B/Victoria
0.2 mL dose at Day 0
Rochester Clinical Research, Inc., Rochester
University Clinical Research-Deland, LLC, DeLand
Clinical Research Atlanta, Stockbridge
University Clinical Research, Inc, Pembroke Pines
Pharmax Research Clinic, Inc, Miami
Miami Research Associates, South Miami
Clinical Research Associates, Inc, Nashville
Kentucky Pediatric / Adult Research, Bardstown
Sundance Clinical Research, St Louis
The Center for Pharmaceutical Research, PC, Kansas City
Vince and Associates Clinical Research, Overland Park
Meridian Clinical Research, LLC, Omaha
Benchmark Research, Fort Worth
Benchmark Research, Austin
Advanced Clinical Research, West Jordan
Benchmark Research, San Francisco
Benchmark Research, Sacramento
California Research Foundation, San Diego
Lead Sponsor
MedImmune LLC
INDUSTRY